Kidney involvement in COVID-19 and rationale for extracorporeal therapies
- PMID: 32273593
- PMCID: PMC7144544
- DOI: 10.1038/s41581-020-0284-7
Kidney involvement in COVID-19 and rationale for extracorporeal therapies
Abstract
The prevalence of direct kidney involvement in novel coronavirus disease (COVID-19) is low, but such involvement is a marker of multiple organ dysfunction and severe disease. Here, we explore potential pathways of kidney damage and discuss the rationale for extracorporeal support with various blood purification strategies in patients who are critically ill with COVID-19.
Conflict of interest statement
In the past 3 years, C.R. has been a consultant or advisory board member for ASAHI, Astute, Baxter, Biomerieux, B. Braun, Cytosorbents, ESTOR, Fresenius Medical Care, General Electric, Medtronic and Toray. In the past 3 years T.R. has been a consultant or advisory board member for Baxter, B. Braun and Eurofarma.
References
-
- Ministero della Salute. Covid-19. Situazione in Italia. Ministero della Salute. Salute.govhttp://www.salute.gov.it/imgs/C_17_pagineAree_5351_30_file.pdf (2020).
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical